Natural Biogenex approves rights issue of 11,11,200 shares

Natural Biogenex Private Limited, a material subsidiary of Natural Capsules Limited , has approved a rights issue to raise capital through the issuance of equity shares. The board of Natural Biogenex Private Limited sanctioned the issuance of 11,11,200 equity shares with a face value of ₹10 each for cash at par. The total issue size aggregates to ₹1,11,12,000.

The approval was granted during a board meeting held on May 27, 2026. The intimation regarding this decision was submitted under Regulation 30(9) of the SEBI (LODR) Regulations, 2015. The filing was made to BSE Limited and the National Stock Exchange of India Limited to inform the exchanges about the corporate action undertaken by the material subsidiary.

Rights Issue Details

The rights issue involves the following key parameters:

Particulars	Details
Total shares offered	11,11,200 Equity shares
Face value	₹10 per share
Issue price	₹10 (at par)
Total aggregate amount	₹1,11,12,000

The shares are being offered on a rights basis to eligible shareholders of the material subsidiary. The proceeds from the issue are intended to bolster the financial resources of Natural Biogenex Private Limited.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-3.19%	+5.34%	+2.53%	-8.06%	-20.29%	-34.83%

Natural Capsules Limited has announced that its board of directors will meet on Wednesday, May 27, 2026. The primary agenda for the meeting is to consider and approve the audited standalone and consolidated financial statements of the company for the quarter and year ended March 31, 2026.

The meeting is being convened in accordance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) 2015. Apart from the financial results, the board will also discuss any other matters with the permission of the Chairman.

Trading Window Closure

In compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company’s internal code of conduct, the trading window for dealing in the equity shares of the company has been closed. This restriction applies to all designated persons and their immediate relatives.

The closure of the trading window became effective from April 1, 2026. It will remain closed until the conclusion of 48 hours after the declaration of the financial results for the quarter and year ended March 31, 2026.

Meeting Details

The following table summarizes the key details regarding the upcoming board meeting and the trading window closure:

Event	Date / Status
Board Meeting Date	May 27, 2026
Financial Period	Quarter/Year ended March 31, 2026
Trading Window Closure	Effective from April 1, 2026
Trading Window Reopening	48 hours after result declaration